IBRI RESEARCH PUBLISHED: Metabolic roles of G protein-coupled receptor signaling in obesity and type 2 diabetes

March 08, 2021


The incidence of obesity and type 2 diabetes (T2D) has been increasing steadily worldwide. It is estimated that by 2045 more than 800 million people will be suffering from diabetes.

Despite the advancements in modern medicine, more effective therapies for treating obesity and T2D are needed. G protein-coupled receptors (GPCRs) have emerged as important drug targets for various chronic diseases, including obesity, T2D and liver diseases.

During the past two decades, many laboratories worldwide focused on understanding the role of GPCR signaling in regulating glucose metabolism and energy homeostasis. The information gained from these studies can guide the development of novel therapeutic agents.

In this review, we summarize recent studies providing insights into the role of GPCR signaling in peripheral, metabolically important tissues such as pancreas, liver, skeletal muscle and adipose tissue, focusing primarily on the use of mutant animal models and human data.

To read the complete research article, go to The FEBS Journal.